February 22, 2022 by Chain Drug Review
Dr. Reddy’s Laboratories North America Generics, Marc Kikuchi
February 21, 2022, Pharmacy, Supplier News
PRINCETON, N.J. — Marc Kikuchi, chief executive officer of Dr. Reddy’s Laboratories North America Generics, has always looked to the future while managing the present. That philosophy was important when he joined the company in February 2019 — just about a year before COVID and its variants washed over the globe and upended businesses. His
August 12, 2020 by Chain Drug Review
ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, Dr. Reddy's Laboratories, Marc Kikuchi
Pharmacy, Supplier News
PRINCETON, N.J. – Dr. Reddy’s announced the launch of ciprofloxacin 0.3% and dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring
May 7, 2020 by Chain Drug Review
4 mcg/mL Single-dose Ampules, desmopressin acetate injection USP, Dr. Reddy's Laboratories, Marc Kikuchi
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s announced the launch of desmopressin acetate injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9
March 23, 2020 by Chain Drug Review
2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, Dr. Reddy's Laboratories, Marc Kikuchi, Naloxone Hydrochloride Injection USP
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s Laboratories announced Monday the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring our second product to market that has been
March 18, 2020 by Chain Drug Review
Dr. Reddy’s, Marc Kikuchi, ziprasidone mesylate for injection
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s has launched ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration. “We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from
February 10, 2020 by Chain Drug Review
Dr. Reddy’s, Marc Kikuchi, Syprine, trientine hydrochloride capsules
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s announced the launch of trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration. “We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, chief executive officer and head
February 21, 2019 by Chain Drug Review
buprenorphine and naloxone sublingual Film, Dr. Reddy’s, Marc Kikuchi, Suboxone (buprenorphine and naloxone) sublingual film
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s Laboratories announced this week the re-launch of its buprenorphine and naloxone sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the U.S. market. The re-launch comes on the heels of a favorable
February 1, 2019 by Chain Drug Review
Dr. Reddy’s, Marc Kikuchi
Supplier News
PRINCETON, N.J. — Marc Kikuchi has been named chief executive officer of North American generics at Dr. Reddy’s Laboratories Ltd. “Dr. Reddy’s is a great company with a wide portfolio and remarkable heritage,” says Kikuchi. “I am excited to join Dr. Reddy’s and look forward to leveraging my past experiences to steer the company’s new